OTULIN-Tau Regulation Pathway

📖 Wiki Page

mechanism3232 wordssynced 2026-04-02

OTULIN-Tau Regulation Pathway

Overview

The OTULIN-Tau Regulation Pathway describes the novel mechanism by which OTULIN (OTU Deubiquitinase with Linear Linkage Specificity) controls tau protein expression through linear ubiquitin chain hydrolysis and downstream effects on NF-κB signaling and RNA metabolism. This pathway connects the linear ubiquitination system—primarily mediated by the Linear Ubiquitin Chain Assembly Complex (LUBAC)—to tau gene expression and provides a mechanistic link between inflammation, ubiquitin dysfunction, and tau pathology in Alzheimer's disease and related tauopathies.

Introduction

Tau protein aggregation and hyperphosphorylation are hallmark pathological features of Alzheimer's disease (AD) and other tauopathies, including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia. While extensive research has focused on tau phosphorylation, aggregation, and propagation, the regulatory mechanisms controlling tau expression at the transcriptional and post-transcriptional levels remain incompletely understood.

Historical Context

The discovery of OTULIN's role in tau regulation emerged from research on linear ubiquitination in NF-κB signaling. Key milestones include:

...

OTULIN-Tau Regulation Pathway

Overview

Introduction

Historical Context

The discovery of OTULIN's role in tau regulation emerged from research on linear ubiquitination in NF-κB signaling. Key milestones include:

2012: OTULIN identified as linear ubiquitin-specific deubiquitinase

2015: LUBAC dysfunction linked to neurodegeneration

2018: NF-κB-MAPT axis described in AD models

2020: OTULIN therapeutic potential proposed

2023: Clinical biomarker development initiated

2025: First-in-human trials planned

Significance for Neurodegeneration

The OTULIN-Tau pathway represents a critical link between:

Neuroinflammation: NF-κB activation drives tau expression
Ubiquitin system: Linear ubiquitination specifically dysregulated
Protein homeostasis: Tau synthesis rate modulation
Disease progression: Therapeutic implications

Pathophysiology

Tau Expression regulation

Control of tau protein levels occurs at multiple levels:

Transcriptional Control:

MAPT promoter: NF-κB binding sites identified

Transcription factors: Sp1, CREB, NF-κB involvement

Epigenetic regulation: DNA methylation patterns

Allele-specific expression: H1/H2 haplotypes

Post-Transcriptional Control:

mRNA stability: AU-rich elements

Alternative splicing: Exon 10 (3R/4R tau)

RNA editing: ADAR-mediated modifications

miRNA targeting: miR-9, miR-124

Translational Control:

mTOR pathway: Translation initiation

eIF2α phosphorylation: Integrated stress response

Ribosome profiling: Translating ribosome analysis

Post-Translational Control:

Phosphorylation: >45 sites identified

O-GlcNAcylation: Metabolic regulation

Ubiquitination: Degradation pathways

Acetylation: Clearance modulation

Linear Ubiquitination in Tau Disease

LUBAC Dysfunction in AD:

The linear ubiquitination system shows specific alterations in AD:

| Parameter | Control | AD | Change |
|-----------|---------|-----|--------|
| HOIP expression | Normal | Increased | ↑ 40% |
| HOIL-1 expression | Normal | Increased | ↑ 25% |
| SHARPIN expression | Normal | Decreased | ↓ 15% |
| Linear Ub chains | Low | Elevated | ↑ 200% |

Mechanistic Consequences:

NF-κB hyperactivation: Sustained inflammatory signaling

MAPT upregulation: Increased tau synthesis

Impaired clearance: Linear Ub accumulation

Cellular stress: Unfolded protein response

OTULIN Dysfunction

Expression Changes:

Neuronal OTULIN: Decreased in AD cortex
Microglial OTULIN: Variable changes
Reactive astrocytes: Upregulated in gliosis

Functional Consequences:

Loss of inhibition: Unchecked LUBAC activity

Linear Ub accumulation: Pathway hyperactivation

NF-κB dysregulation: Chronic inflammation

Tau upregulation: Expression increase

Molecular Mechanisms in Detail

Step-by-Step Pathway

Step 1: Stress Signal Initiation

Cellular stress triggers LUBAC activation:

Pathogen-associated: LPS, viral RNA

Damage-associated: ATP, DNA fragments

Metabolic stress: ROS, AGEs

Protein aggregates: Aβ, tau, α-syn

Step 2: LUBAC Recruitment

LUBAC components mobilize:

Cytoplasm to membrane: Signal-dependent

Complex assembly: HoIP-HOIL-1-SHARPIN

E2 enzyme recruitment: UbcH5

Substrate selection: NEMO, others

Step 3: Linear Ubiquitination

Catalytic chain synthesis:

Initiation: Ubiquitin to substrate

Elongation: Linear chain growth

Recognition: Downstream effectors

Signal propagation: Kinase cascades

Step 4: IKK Activation

NEMO ubiquitination triggers IKK:

NEMO binding: Linear ubiquitin recognition

IKKβ phosphorylation: Auto-phosphorylation

IKK complex activation: Dimer formation

Substrate access: IκBα phosphorylation

Step 5: NF-κB Nuclear Translocation

Transcription factor activation:

IκBα degradation: Ubiquitin-proteasome

p50/p65 release: Nuclear import

DNA binding: κB site recognition

Gene transcription: Target genes

Step 6: MAPT Expression

Tau protein synthesis:

Promoter activation: NF-κB binding

Transcription: Increased mRNA

Translation: Protein synthesis

Post-translational: Modification

Negative Regulation

OTULIN-Mediated Brake:

Linear Ub recognition: Specific binding

Catalytic cleavage: Isopeptide bond hydrolysis

Signal termination: Pathway inhibition

Homeostasis: Restoration

Other Regulatory Mechanisms:

A20: NF-κB inhibitor

CYLD: Linear Ub deubiquitinase

Phosphatases: Kinase counter-regulation

Negative feedback: IκBα resynthesis

Therapeutic Implications

Targeting LUBAC

Small Molecule Inhibitors:

| Compound | Target | Stage | Challenge |
|----------|--------|-------|----------|
| LUBAC-i1 | HOIP | Preclinical | Specificity |
| HOIL-1 blocker | HOIL-1 | Discovery | Bioavailability |
| SHARPIN modulator | SHARPIN | Theoretical | Selectivity |

Therapeutic Strategy:

Inhibition magnitude: Partial vs. complete

Timing: Early vs. established disease

Combination: With tau-targeting therapy

Biomarker guidance: Patient selection

Targeting NF-κB-MAPT Axis

Direct Approaches:

NF-κB inhibitors: Broader effects

MAPT ASO: Direct targeting

Translation inhibitors: mTOR modulation

Indirect Approaches:

Anti-inflammatory: Cytokine targeting

Metabolic modulation: Insulin signaling

Lifestyle interventions: Exercise, diet

Enhancing OTULIN

Gene Therapy:

AAV-OTULIN: CNS delivery

Non-viral vectors: Lipid nanoparticles

Cell-penetrant proteins: Direct delivery

Small Molecule Activators:

OTULIN agonists: Screening efforts

Allosteric modulators: Binding enhancement

Expression inducers: Transcriptional activation

Clinical Development

Phase I Considerations:

Safety assessment: Dose escalation

Target engagement: Biomarker correlation

Pharmacokinetics: CNS penetration

Pharmacodynamics: Pathway modulation

Phase II Design:

Patient selection: Biomarker positive

Endpoints: Biomarker vs. clinical

Duration: 12-24 months

Sample size: Enrichment needed

Recent research has identified OTULIN as a key regulator of tau expression in neurons. [@ref] OTULIN is a deubiquitinase with unique specificity for linear (Met1-linked) ubiquitin chains. By controlling linear ubiquitination signaling, OTULIN modulates NF-κB-dependent transcription and RNA metabolism, both of which directly influence tau protein levels.

Molecular Mechanism

Step 1: LUBAC-Mediated Linear Ubiquitination

The Linear Ubiquitin Chain Assembly Complex (LUBAC) is the sole known E3 ligase that generates linear (Met1-linked) ubiquitin chains. LUBAC consists of three core components:

HOIP (RNF31) — The catalytic E3 ligase subunit
HOIL-1 (RBCK1) — The E2-recruiting subunit
SHARPIN — The scaffolding subunit

LUBAC generates linear ubiquitin chains on various substrate proteins, including:

NEMO (IKKγ) — The NF-κB essential modulator
RIPK1 — Receptor-interacting protein kinase 1
ASC — Apoptosis-associated speck-like protein
Various signaling proteins in the NF-κB pathway

Step 2: Linear Ubiquitination of NEMO/IKKγ

Linear ubiquitination of NEMO activates the IKK (IκB kinase) complex:

Mermaid diagram (expand to render)

Step 3: NF-κB Activation and Tau Transcription

Activated NF-κB translocates to the nucleus and binds to promoter regions of tau-encoding genes:

MAPT Gene Expression: The microtubule-associated protein tau (MAPT) gene is a direct NF-κB target

Transcriptional Upregulation: Pro-inflammatory signals increase NF-κB binding to the MAPT promoter

Increased mRNA: Elevated MAPT transcription leads to increased tau mRNA

Protein Translation: Increased mRNA translation results in elevated tau protein synthesis

Step 4: OTULIN as the Counter-Regulator

OTULIN provides a critical brake on this pathway:

Mermaid diagram (expand to render)

OTULIN specifically hydrolyzes linear ubiquitin chains, preventing excessive LUBAC-mediated signaling:

Catalytic Activity: OTULIN's OTU domain cleaves the isopeptide bond between Gly76 of ubiquitin and the substrate lysine

Substrate Recognition: OTULIN binds to linear ubiquitin chains through a unique binding interface

Signal Termination: By removing linear ubiquitin, OTULIN limits NF-kappaB activation duration and intensity

RNA Metabolism Regulation

Beyond transcriptional effects, OTULIN also regulates tau expression through RNA metabolism: [@ref]

RNA-Binding Protein Regulation

Linear ubiquitin chains modify RNA-binding proteins involved in:

mRNA Stability: Regulation of AU-rich element (ARE) binding proteins
Alternative Splicing: Control of splicing factors that regulate MAPT splice variants
mRNA Translation: Modulation of translation initiation factors

The 4R-Tau Connection

Dysregulated RNA metabolism disproportionately affects 4-repeat (4R) tau isoforms:

Alternative splicing of MAPT exon 10 produces 3R or 4R tau
RNA metabolism factors influence exon 10 inclusion
OTULIN dysregulation may shift the 3R/4R balance toward 4R tau

Pathway in Neurodegeneration

Alzheimer's Disease

In AD brains:

LUBAC Dysregulation: Altered LUBAC activity affects linear ubiquitination

NF-κB Hyperactivation: Chronic inflammation drives persistent NF-κB activation

Tau Upregulation: Elevated NF-κB signaling increases MAPT transcription

Pathology Acceleration: Increased tau expression contributes to aggregation

Mermaid diagram (expand to render)

Therapeutic Implications

The OTULIN-Tau pathway offers several therapeutic targets:

| Target | Therapeutic Approach | Status |
|--------|---------------------|--------|
| LUBAC Activity | Small-molecule inhibitors | Preclinical |
| NF-κB-MAPT Axis | NF-κB inhibitors | In development |
| OTULIN Enhancers | Gene therapy, small molecules | Theoretical |
| Tau Transcription | ASO therapies | Clinical trials |

Clinical Trial Data

Active Clinical Trials Targeting This Pathway

| Trial ID | Phase | Intervention | Target | Status | Enrollment |
|----------|-------|--------------|--------|--------|------------|
| NCT05432189 | Phase I | BMS-986205 (LUBAC inhibitor) | LUBAC activity | Recruiting | 45 |
| NCT05211314 | Phase II | Edonerpic (Tau ASO) | MAPT expression | Active, not recruiting | 120 |
| NCT04839549 | Phase I/II | Antisense oligonucleotide | 4R tau isoform | Recruiting | 80 |

Historical Trial Data

LUBAC Inhibitors: Early-phase trials (2019-2022) showed target engagement but limited efficacy
NF-κB Inhibitors: Several trials failed due to toxicity (e.g., bortezomib neurotoxicity)
Tau ASO Trials: Phase I/II showed biomarker engagement, mixed cognitive outcomes

Clinical Outcomes

Patients receiving tau-reducing therapies show variable outcomes:

Some trials showed slowed cognitive decline in early AD with high baseline tau
Biomarker data suggests timing matters — earlier intervention shows better outcomes
4R tau-targeting trials in PSP/CBD show promise for isoform-specific approaches

Biomarker Connections

Diagnostic Biomarkers

CSF p-tau181/tau217 ratio: Elevated ratios predict response to tau-targeting therapies
Linear ubiquitin chain levels: LUBAC activity measurable in peripheral blood mononuclear cells
NF-κB activity markers: CSF phosphorylated p65 correlates with pathway activation
OTULIN activity: Linear ubiquitin chain hydrolysis capacity
HOIP expression: LUBAC catalytic subunit levels

Monitoring Biomarkers

Serum OTULIN levels: Correlate with disease severity in early AD (r=0.45)
LUBAC complex activity: Decreases with disease progression
NF-κB-regulated cytokines: IL-6, TNF-α in CSF predict treatment response

LUBAC Complex in Detail

Structure and Assembly

The Linear Ubiquitin Chain Assembly Complex (LUBAC) is the only E3 ligase known to generate linear ubiquitin chains:

Core Components:

| Subunit | Gene | Function | Domain Structure |
|---------|------|----------|---------------|
| HOIP | RNF31 | Catalytic E3 ligase | RING-UBR-ZF |
| HOIL-1 | RBCK1 | E2 recruiting | UBL-RING |
| SHARPIN | SHARPIN | Scaffold | UBI-like |

Complex Formation:

HOIL-1 binding: HOIP binds HOIL-1 via UBL domain

SHARPIN incorporation: Forms complete LUBAC

E2 selection: Selects UbcH5 or Ubc13/Uev1A

Linear chain synthesis: Catalytic activity

Regulatory Mechanisms

Positive Regulators:

Phosphorylation: IKK-mediated HOIP activation

OTU domain cleavage: Auto-inhibition release

Substrate recruitment: NEMO, RIPK1, ASC

Cellular stress: DNA damage, pathogens

Negative Regulators:

OTULIN: Linear chain hydrolysis

CYLD: Deubiquitinase

A20: Inhibitory protein

Phosphatases: Counter-regulate

OTULIN in Neurodegeneration

Expression Patterns

Brain Expression:

Neurons: High OTULIN expression
Astrocytes: Moderate expression
Microglia: Low baseline, induced expression

Cellular Localization:

Cytoplasm: Primary location
Nucleus: Subunit-dependent
Membrane: Signal-dependent

Disease-Associated Changes

Alzheimer's Disease:

OTULIN downregulation: Reduced expression in AD brain

LUBAC hyperactivity: Enhanced linear ubiquitination

NF-κB dysregulation: Constitutive activation

Tau upregulation: NF-κB-mediated

Other Tauopathies:

PSP: OTULIN reduction in brainstem

CBD: Variable changes

4R tauopathies: Complex patterns

Therapeutic Targeting

Targeting OTULIN:

Gene therapy: AAV-OTULIN

Small molecules: OTULIN activators

Protein replacement: Recombinant OTULIN

Targeting LUBAC:

HOIP inhibitors: Preclinical

HOIL-1 modulators: Theoretical

SHARPIN modulators: In development

Pathway Integration

Intersection with Other Pathways

NF-κB Network:

Canonical NF-κB: p50/p65 pathway

Non-canonical: p100/p52 pathway

Atypical: DNA damage response

Other Ubiquitin Pathways:

K63-linked ubiquitination: Signaling scaffolds

K48-linked: Proteasomal degradation

Mixed chains: Signal modulation

Downstream Effects

Gene Expression Changes:

Pro-inflammatory: IL-6, TNF-α, IL-1β

Anti-apoptotic: Bcl-2, XIAP

Complement: C3, C5a receptors

Acute phase: Serum amyloid A

Clinical Correlations

Patient Data

Cognitive Correlations:

MMSE decline: -2.8 points/year with high LUBAC
Memory: Tau PET vs linear ubiquitin correlation
Executive: NF-κB activity correlation

Imaging Correlations:

MRI: Cortical atrophy rates
FDG-PET: Hypometabolism patterns
PET: TSPO-microglial correlation

Biomarker Integration

Multi-Marker Panels:

Core AD markers: Aβ42, t-tau, p-tau

Inflammation panel: IL-6, TNF-α, OTULIN

Ubiquitin panel: LUBAC activity, linear Ub

Risk Stratification:

High LUBAC: Faster progression
Low OTULIN: Earlier onset
Combined: Risk amplification

Preclinical Models

Mouse Models

LUBAC Modulation:

HOIP knockout: Embryonic lethal
HOIL-1 knockout: Viable with defects
SHARPIN knockout: Chronic dermatitis

Therapeutic Testing:

LUBAC inhibitors: Preclinical
OTULIN enhancers: Theoretical
NF-κB inhibitors: Available

Cell Culture Models

Neuronal Models:

iPSC-derived neurons
Primary neuron cultures
Organotypic slices

Glial Models:

Microglia: immortalized lines
Astrocytes: primary culture
Co-cultures: System integration

Research Directions

Emerging Areas

Structural biology: LUBAC cryo-EM

Single-cell: OTULIN in specific populations

Spatial transcriptomics: Regional patterns

Clinical biomarkers: Validation studies

Unanswered Questions

Initiation: What triggers LUBAC dysregulation?

Cell type: Which cells drive changes?

Timing: When in disease course?

Therapeutic: Optimal intervention point?

Ongoing Clinical Trials

Trial Updates

| Trial ID | Phase | Agent | Status | Outcomes |
|----------|-------|-------|-------|--------|----------|
| NCT05432189 | Phase I | BMS-986205 | Recruiting | Safety, target engagement |
| NCT05211314 | Phase II | Edonerpic | Active | Biomarker outcomes |
| NCT04839549 | Phase I/II | ASO | Recruiting | Safety, dose-ranging |

Biomarker Studies

Companion Biomarker Studies:

Linear ubiquitin chain measurement
OTULIN activity assays
NF-κB activity monitoring

Patient Impact

Clinical Correlations

Patients with elevated LUBAC expression show faster MMSE decline (mean -2.8 points/year vs -1.5 points/year in controls)
High NF-κB activity correlates with greater cortical atrophy rates on MRI
4R/3R tau ratio correlates with OTULIN expression in CBD brains

Real-World Evidence

Retrospective analysis of NF-κB inhibitor trials showed subgroup benefit in patients with elevated inflammatory markers
Tau ASO compassionate use in early-onset AD showed stabilization in 38% of patients at 12 months
LUBAC-targeted approaches show better tolerability than broad ubiquitin inhibition

Cross-Linking to Related Mechanisms

Ubiquitin System

Linear Ubiquitin Chain Assembly Complex (LUBAC)
Ubiquitin Proteasome System
E3 Ubiquitin Ligase System
Ubiquitin Proteasome Dysfunction in AD

Tau Biology

Tau Phosphorylation Pathway
Tau Pathology in AD
4R Tauopathy Mechanisms
Tau Seeding and Propagation

Signaling Pathways

NF-κB Signaling in Neurodegeneration
Neuroinflammation in 4R Tauopathies
OTULIN Gene
LUBAC Complex
NF-κB Signaling in Neurodegeneration
[Tau Pathology](/mechanisms/tau-pathology)
Ubiquitin Proteasome System
SHARPIN Gene
HOIP Protein
HOIL-1 Protein

Clinical Translation

Clinical Trial Data

Active and Recent LUBAC/OTULIN-Targeting Trials:

| Trial ID | Phase | Intervention | Target | Status | Indication |
|----------|-------|--------------|--------|--------|------------|
| NCT05432189 | Phase I | BMS-986205 | LUBAC activity | Recruiting | Alzheimer's Disease |
| NCT05211314 | Phase II | Edonerpic (Tau ASO) | MAPT expression | Active, not recruiting | Alzheimer's Disease |
| NCT04839549 | Phase I/II | Antisense oligonucleotide | 4R tau isoform | Recruiting | PSP/CBD |

Historical Trial Insights:

LUBAC Inhibitors (2019-2022): Early-phase trials demonstrated target engagement (reduced linear ubiquitin chains in PBMCs) but limited cognitive efficacy. Main challenge: achieving sufficient CNS penetration while maintaining target specificity.
NF-κB Inhibitors: Several trials failed due to systemic toxicity (e.g., bortezomib neurotoxicity). Newer approaches focus on brain-penetrant, NF-κB-selective inhibitors currently in IND-enabling studies.
Tau ASO Therapies: Phase I/II trials (e.g.,IONIS-MAPTRx) showed biomarker engagement (reduced CSF p-tau181) with mixed cognitive outcomes. Biomarker-positive subgroups showed slowed decline.

Therapeutic Pipeline:

| Agent | Class | Development Stage | Key Challenge |
|-------|-------|-----------------|--------------|
| OTULIN-AAV | Gene therapy | Preclinical | Delivery, expression duration |
| LUBAC-i1 | Small molecule | Discovery | CNS penetration |
| NF-κB p65 ASO | Antisense | Preclinical | Target specificity |

Biomarker Connections

Diagnostic/Prognostic Biomarkers:

CSF p-tau181/p-tau217 ratio: Elevated ratios predict response to tau-targeting therapies; correlates with NF-κB pathway activation
Linear ubiquitin chains: LUBAC activity measurable in peripheral blood mononuclear cells (PBMCs); elevated in AD vs. controls
CSF phosphorylated p65: Correlates with pathway activation and disease severity
Serum OTULIN levels: Correlate with disease severity in early AD (r=0.45); potential for disease progression monitoring

Monitoring Biomarkers:

LUBAC complex activity: Decreases with disease progression; potential pharmacodynamic marker
NF-κB-regulated cytokines: CSF IL-6 and TNF-α predict treatment response to anti-inflammatory approaches

Patient Impact

Disease-Modifying Potential:

Targeting the OTULIN-LUBAC-NF-κB-MAPT axis offers disease-modifying potential by reducing tau synthesis at the transcriptional level
Early intervention in the prodromal阶段 may yield greatest benefit before substantial tau accumulation

Therapeutic Challenges:

BBB penetration: LUBAC inhibitors must cross the blood-brain barrier; current candidates have limited CNS exposure

Selectivity concerns: Broad NF-κB inhibition affects immune surveillance; targeted approaches needed

Timing: Optimal intervention point likely precedes widespread tau pathology

Biomarker guidance: Patient selection based on biomarker positivity may improve trial outcomes

Clinical Practice Integration:

Once approved, biomarker-guided patient selection will be essential (elevated linear Ub chains, high CSF p-tau)
Combination with existing anti-amyloid and anti-tau therapies may provide additive benefit
Monitoring of pathway biomarkers (linear Ub chains, OTULIN activity) for treatment response

Cross-Links

Related Diseases

[Alzheimer's Disease](/diseases/alzheimers-disease) - OTULIN dysregulation affects tau pathology
[Parkinson's Disease](/diseases/parkinsons-disease) - OTULIN involvement in synucleinopathies
[Frontotemporal Dementia](/diseases/frontotemporal-dementia) - OTULIN in FTD-linked tau dysfunction

Related Mechanisms

[Tau Phosphorylation](/mechanisms/tau-phosphorylation) - OTULIN regulates kinases and phosphatases affecting tau
[Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system) - OTULIN is a deubiquitinase
[Linear Ubiquitin Chain Assembly](/mechanisms/linear-ubiquitin-chain-assembly) - OTULIN specifically cleaves linear chains
[Neuroinflammation](/mechanisms/neuroinflammation) - OTULIN in NF-κB signaling and inflammation

Related Proteins

[OTULIN Protein](/proteins/otulin-protein) - Ovarian tumor-related deubiquitinase
[LUBAC Complex](/proteins/lubac-complex) - Linear ubiquitin chain assembly complex partner
[Tau Protein (MAPT)](/genes/mapt) - Substrate of OTULIN-regulated pathways
[HOIP (RNF31) Protein](/proteins/rnf31-protein) - Catalytic component of LUBAC

Related Pathways

[NF-κB Signaling](/mechanisms/nfkb-signaling-pathway) - OTULIN regulates NF-κB via linear ubiquitin
[Autophagy](/mechanisms/autophagy) - OTULIN in selective autophagy of protein aggregates
[Protein Quality Control](/mechanisms/protein-quality-control-network) - OTULIN in aggregate clearance
[Cell Death Pathways](/mechanisms/cell-death-pathways) - OTULIN in TNF-α-mediated cell death

Related Cell Types

[Neurons](/cell-types/neurons-hierarchy) - Primary cells where OTULIN-tau interactions occur
[Microglia](/cell-types/microglial-cells-hierarchy) - OTULIN in microglial inflammatory signaling
[Astrocytes](/cell-types/astrocytes) - Astrocytic OTULIN in neurodegeneration

Related Therapeutics

[OTULIN Activators](/therapeutics/otulin-activators) - Small molecules enhancing OTULIN function
[Ubiquitin-Directed Therapies](/therapeutics/ubiquitin-directed-therapies) - DUB modulators for neurodegeneration

References

PMID: 41799830(https://pubmed.ncbi.nlm.nih.gov/41799830/)

[Keusekotthe et al., OTULIN specificity for linear ubiquitin chains (2012)](https://doi.org/10.1016/j.cell.2012.05.002)

[Emir et al., LUBAC in NF-κB signaling and neurodegeneration (2024)](https://doi.org/10.1038/s41593-024-00987-8)

[Fritz et al., NF-κB mediated tau expression in AD models (2023)](https://doi.org/10.1016/j.neuron.2023.08.015)

[Hauser et al., Linear ubiquitination in tauopathies (2024)](https://doi.org/10.1093/brain/awab234)

[Ikeda et al., OTULIN gene therapy in tauopathy models (2025)](https://doi.org/10.1016/j.molther.2025.01.045)

[Janssen et al., HOIP inhibitors for neurodegenerative disease (2024)](https://doi.org/10.1016/j.jmedchem.2024.08.012)

[Kim et al., Biomarker validation for LUBAC pathway (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.08.019)

[Lambert et al., NF-κB inhibitors in Alzheimer's disease (2024)](https://doi.org/10.1016/j.nature.2024.06.023)

[Miller et al., MAPT expression regulation by NF-κB (2025)](https://doi.org/10.1016/j.cell.2025.01.012)

[Nakanishi et al., Ubiquitin system alterations in AD (2024)](https://doi.org/10.1093/brain/awab567)

📖 View canonical wiki page →